Physician profile
Donald A Mazzulla
NPI 1740443522
$215,067.24
in general payments reported to CMS, 2019-2025
19 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $22K · 2021: $20K · 2022: $39K · 2023: $40K · 2024: $54K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $53K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Travel and Lodging: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $10K · Food and Beverage: $6,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $53,176.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,271.08 |
| Travel and Lodging | $10,966.87 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,155.00 |
| Food and Beverage | $6,418.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $76,032.33 | 2019-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $51,967.62 | 2022-2025 | Syfovre |
| Allergan, INC. | $49,239.27 | 2019-2021 | |
| Abbvie INC. | $20,021.40 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $9,979.31 | 2025 | Yutiq, Purified Cortrophin Gel, Iluvien |
| Regeneron Healthcare Solutions, INC. | $3,854.60 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $927.78 | 2022-2024 | Clareon, Centurion, Argos |
| Regeneron Pharmaceuticals, INC. | $638.38 | 2021-2025 | Eylea Hd, Eylea |
| Coherus Oncology, INC. | $529.70 | 2023 | |
| Mallinckrodt Hospital Products INC. | $490.92 | 2023-2025 | Acthar |
| Astellas Pharma US INC | $380.99 | 2023-2025 | Izervay |
| Genentech USA, INC. | $151.73 | 2022-2023 | Vabysmo |
| Glaukos Corporation | $149.07 | 2022 | |
| Genentech, INC. | $147.23 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $121.68 | 2025 | Xdemvy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $119.78 | 2024 | Oxervate |
| Spark Therapeutics, INC. | $114.75 | 2019 | |
| Sun Pharmaceutical Industries INC. | $110.85 | 2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $89.85 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Mazzulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.